Journal Article

Case-based review: pediatric medulloblastoma

Cassie N Kline, Roger J Packer, Eugene I Hwang, David R Raleigh, Steve Braunstein, Corey Raffel, Pratiti Bandopadhayay, David A Solomon, Mariam Aboian, Soonmee Cha and Sabine Mueller

in Neuro-Oncology Practice

Volume 4, issue 3, pages 138-150
Published in print September 2017 | ISSN: 2054-2577
Published online August 2017 | e-ISSN: 2054-2585 | DOI:
Case-based review: pediatric medulloblastoma

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Palliative Medicine
  • Radiation Oncology
  • Clinical Radiology
  • Neurosurgery


Show Summary Details



Medulloblastoma is the most common malignant brain tumor affecting children. These tumors are high grade with propensity to metastasize within the central nervous system and, less frequently, outside the neuraxis. Recent advancements in molecular subgrouping of medulloblastoma refine diagnosis and improve counseling in regards to overall prognosis. Both are predicated on the molecular drivers of each subgroup—WNT-activated, SHH-activated, group 3, and group 4. The traditional therapeutic mainstay for medulloblastoma includes a multimodal approach with surgery, radiation, and multiagent chemotherapy. As we discover more about the molecular basis of medulloblastoma, efforts to adjust treatment approaches based on molecular risk stratification are under active investigation. Certainly, the known neurological, developmental, endocrine, and psychosocial injury related to medulloblastoma and its associated therapies motivate ongoing research towards improving treatment for this life-threatening tumor while at the same time minimizing long-term side effects.

Keywords: chemotherapy; medulloblastoma; radiation; risk stratification; targeted therapy

Journal Article.  7696 words.  Illustrated.

Subjects: Medical Oncology ; Palliative Medicine ; Radiation Oncology ; Clinical Radiology ; Neurosurgery

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.